Eton Pharmaceuticals
About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc., a privately held company, is focused on the development and commercialization of innovative sterile injectable product candidates utilizing the FDA 505(b)(2) regulatory pathway.81 articles with Eton Pharmaceuticals
-
The U.S. Food and Drug Administration has two PDUFA dates this week, one for a type of epilepsy and the other for a triple-combination drug for cystic fibrosis. Here’s a look.
-
Eton Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Financial Results
3/5/2020
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today reported financial results for the fourth quarter ended December 31, 2019 and provided an update on business progress.
-
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, March 5, 2020
2/27/2020
Eton Pharmaceuticals, Inc, a specialty pharmaceutical company focused on developing and commercializing innovative drug products, announced that it will report fourth quarter and full year 2019 financial and operating results on Thursday, March 5, 2020.
-
Eton Pharmaceuticals Provides Update on ET-105 Program
2/19/2020
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today provided an update on its ET-105 product candidate, which is currently under review with the U.S. Food and Drug Administration (FDA).
-
Eton Pharmaceuticals to Present at the 9th Annual SVB Leerink Healthcare Conference
2/13/2020
Eton Pharmaceuticals, Inc. announced that Sean Brynjelsen, Chief Executive Officer, will present at the 9th Annual SVB Leerink Healthcare Conference on Tuesday, February 25, 2020 in New York, NY.
-
Eton Pharmaceuticals and Xellia Pharmaceuticals Announce Biorphen® (phenylephrine HCl) Co-Promotion Agreement
1/21/2020
Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, announced it has entered into a co-promotion agreement with Xellia Pharmaceuticals for the promotion of Biorphen® (phenylephrine HCl), the first and only FDA approved ready-to-use formulation of phenylephrine injection indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.
-
Eton Pharmaceuticals Announces Commercial Availability of Biorphen® (phenylephrine HCI) Injection
12/2/2019
Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that Biorphen®, the first and only FDA-approved ready-to-use formulation of phenylephrine for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia, is now commercially available
-
Eton Pharmaceuticals Announces Third Quarter Financial Results and Highlights Business Progress
11/14/2019
Eton Pharmaceuticals, Inc reported financial results for the third quarter ended September 30, 2019 and provided an update on business progress.
-
Eton Pharmaceuticals Announces $10 Million Debt Facility with SWK Holdings
11/13/2019
Eton Pharmaceuticals, Inc announced it has entered into a $10 million debt facility with SWK Holdings Corporation.
-
Eton Pharmaceuticals to Report Third Quarter 2019 Financial Results on Thursday, November 14, 2019
11/6/2019
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report third quarter 2019 financial and operating results on Thursday, November 14, 2019.
-
Eton Pharmaceuticals Announces U.S. FDA Approval of Biorphen® (phenylephrine HCI) Injection
10/22/2019
Eton Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved Biorphen®, the first and only FDA-approved ready-to-use formulation of phenylephrine for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.
-
We round out the month of October and start the month of November with four PDUFA dates on the U.S. Food and Drug Administration’s calendar. Here’s a look.
-
Eton Pharmaceuticals Announces Positive Results from Clinical Study Report of ET-104
8/19/2019
ET-104 Successfully Demonstrated Bioequivalence to Currently Approved Oral Solid Formulation
-
Bausch Health Acquires Eton Pharmaceuticals' EM-100 Investigational Eye Drop For The Treatment Of Itchy Eyes Associated With Allergies
2/19/2019
If Approved, EM-100 Will Be the First OTC Preservative-Free Formulation of Its Kind
-
The Nasdaq indicated that there was a record amount of biotech initial public offerings this year, including some individual record-breakers—Moderna, Allogene Therapeutics and Rubius Therapeutics. The total for the year is around $8.2 billion raised, breaking 2014’s record of $6.5 billion.
-
A summary of IPOs from companies in the biotech and pharma world since November 1, 2018.
-
Eton Pharma Reports Positive Top-Line Results from Phase III Trial of EM-100 Ophthalmic Solution
7/24/2018
Eton Pharmaceuticals , Inc., a specialty pharmaceutical company, announced positive top-line results for its phase III study of EM-100 ophthalmic solution. If approved, EM-100 would be the first topical, preservative-free formulation for the treatment of ocular itching associated with allergic conjunctivitis.
-
Eton Pharma Appoints Paul V. Maier To Its Board Of Directors
9/15/2017
-
Eton Pharma Appoints Dr. Norbert Riedel To Its Board Of Directors
9/8/2017
-
Eton Pharma Names Sean Brynjelsen Chief Executive Officer And Director
6/23/2017